KKR completed its $5.89 billion acquisition of Integer Holdings in August, the largest healthcare private equity transaction of the month and the anchor deal in a sector that accounted for the majority of PE activity while global volume collapsed. The medical-device manufacturer acquisition closed without fanfare and now positions KKR as the dominant consolidator in the instrumentation supply chain serving cardiac, neuromodulation, and orthopedic OEMs.
Global private equity dealmaking fell 41% month-over-month in August, with total announced transactions dropping to approximately $47 billion across all sectors. Healthcare represented $18.2 billion of that total, or roughly 39% of global PE volume, with the Integer deal alone comprising nearly a third of healthcare's share. No other sector crossed $8 billion in August activity. The concentration is unusual: healthcare typically represents 18-22% of PE dealmaking in non-crisis periods, and single deals rarely command more than 12-15% of a month's total volume.
The Integer acquisition matters less for the asset itself and more for what it signals about deployment urgency in the current rate environment. KKR paid a 28% premium to Integer's thirty-day average when the deal was announced in May, and the firm moved the transaction from announcement to close in ninety-three days—faster than the 120-150 day average for deals in this size range. That speed indicates either exceptional diligence preparation or a calculated bet that financing windows would tighten before year-end. Integer's $1.4 billion in trailing revenue and 22% EBITDA margins fit the profile of assets that can support leverage even if the Fed holds rates elevated through 2025.
The medical-device angle is worth isolating. Integer does not sell to patients or hospitals—it manufactures components and subsystems for companies like Medtronic, Boston Scientific, and Abbott. The business is B2B, sticky, and largely insulated from reimbursement risk or consumer sentiment. KKR is buying a toll booth on the supply chain, not exposure to procedure volumes. The sector has seen $11.3 billion in PE transactions year-to-date, and Integer represents the largest single check written into component manufacturing rather than end-market exposure. That distinction suggests sophisticated allocators are rotating out of volume-sensitive healthcare plays and into margin-stable infrastructure.
Operators and allocators should watch three follow-on events. First, whether KKR consolidates Integer with any of its existing medical-device platform companies—particularly Avantor or any bolt-ons inside its industrials portfolio—before Q1 2025. Second, whether competing mega-funds deploy similar capital into B2B healthcare infrastructure in the next sixty days, which would confirm the rotation thesis. Third, how Integer's debt is priced in secondary markets over the next ninety days: if spreads tighten, it signals confidence in the Fed's terminal rate; if they widen, it confirms KKR timed the exit from the primary markets well.
The real tell is not that KKR wrote a $5.9 billion check. It is that they wrote it in August, closed it in ninety-three days, and did so into a subsector with no direct patient exposure while the rest of the market pulled back.